FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978171357> ?p ?o ?g. }

• W2978171357 endingPage "S122" @default.
• W2978171357 startingPage "S122" @default.
• W2978171357 abstract "Introduction: Sclerosing mesenteritis (SM) is a rare, chronic fibrosing and inflammatory disorder affecting the small bowel mesentery. Pentoxifylline has anti-inflammatory properties that could potentially benefit this disease. There is limited data on the efficacy of pentoxifylline for other fibroinflammatory disorders. We performed a retrospective chart review of patients with SM who were treated with pentoxifylline. Methods: ICD-9 codes were used to identify patients with SM, and free text search for pentoxifylline was used. Clinical data was abstracted from the electronic medical record and patients were called for followup. Data analysis was performed using JMP version 9.0.1. Results: Eleven patients were identified with median age of 64 years (range 39-75), and 36% were female. At presentation, abdominal pain was present in 10/11 (91%), abdominal distention or bloating was present in 8/11 (73%), and 7/11 (64%) had nausea or vomiting. Eighty-two percent (9/11) had a biopsy-proven SM, while the other 2 patients had characteristic CT findings without biopsy. Imaging findings at diagnosis included mesenteric mass in 6/11 (55%), mesenteritis without mass in 5/11 (45%), and lymphadenopathy in 4/11 (36%). Eight patients were prescribed tamoxifen prior to pentoxifylline; all 8 discontinued use (2 due to thromboembolism, 1 due to intolerance, 5 due to no response). The most common pentoxifylline dose was 400 mg 3 times a day (50% of patients), median duration was 4 months (range 1-30). Long-term follow-up data was available in 7 patients. Five patients were on prednisone while taking pentoxifylline. Two out of 7 patients (28.57%) experienced complete clinical improvement, 2/7 (28.57%) partial improvement, 3/7 (42.86%) no response. One patient had complete resolution of inflammatory changes on abdominal MRI. Two patients experienced nausea secondary to pentoxifylline, 1 of them requiring discontinuation. One patient died from refractory intestinal obstruction. Follicular large-cell lymphoma was diagnosed in 1 patient at follow-up. Conclusion: Pentoxifylline appears to be a reasonable treatment option for patients with SM that did not respond to tamoxifen. It appears to be well-tolerated, with only 1 patient stopping due to side effects. However, larger studies are necessary to better estimate the benefits and side effect profile of pentoxifylline in SM." @default.
• W2978171357 created "2019-10-10" @default.
• W2978171357 creator A5016245381 @default.
• W2978171357 creator A5077344268 @default.
• W2978171357 creator A5077792271 @default.
• W2978171357 date "2014-10-01" @default.
• W2978171357 modified "2023-09-25" @default.
• W2978171357 title "Treatment Outcomes From Pentoxifylline in Sclerosing Mesenteritis" @default.
• W2978171357 doi "https://doi.org/10.14309/00000434-201410002-00403" @default.
• W2978171357 hasPublicationYear "2014" @default.
• W2978171357 type Work @default.
• W2978171357 sameAs 2978171357 @default.
• W2978171357 citedByCount "0" @default.
• W2978171357 crossrefType "journal-article" @default.
• W2978171357 hasAuthorship W2978171357A5016245381 @default.
• W2978171357 hasAuthorship W2978171357A5077344268 @default.
• W2978171357 hasAuthorship W2978171357A5077792271 @default.
• W2978171357 hasConcept C126322002 @default.
• W2978171357 hasConcept C141071460 @default.
• W2978171357 hasConcept C2776956441 @default.
• W2978171357 hasConcept C2780404050 @default.
• W2978171357 hasConcept C2780580376 @default.
• W2978171357 hasConcept C2780955771 @default.
• W2978171357 hasConcept C71924100 @default.
• W2978171357 hasConcept C90924648 @default.
• W2978171357 hasConceptScore W2978171357C126322002 @default.
• W2978171357 hasConceptScore W2978171357C141071460 @default.
• W2978171357 hasConceptScore W2978171357C2776956441 @default.
• W2978171357 hasConceptScore W2978171357C2780404050 @default.
• W2978171357 hasConceptScore W2978171357C2780580376 @default.
• W2978171357 hasConceptScore W2978171357C2780955771 @default.
• W2978171357 hasConceptScore W2978171357C71924100 @default.
• W2978171357 hasConceptScore W2978171357C90924648 @default.
• W2978171357 hasLocation W29781713571 @default.
• W2978171357 hasOpenAccess W2978171357 @default.
• W2978171357 hasPrimaryLocation W29781713571 @default.
• W2978171357 hasRelatedWork W130434534 @default.
• W2978171357 hasRelatedWork W1980123723 @default.
• W2978171357 hasRelatedWork W2062882054 @default.
• W2978171357 hasRelatedWork W2069896043 @default.
• W2978171357 hasRelatedWork W2098294301 @default.
• W2978171357 hasRelatedWork W2320562621 @default.
• W2978171357 hasRelatedWork W2330377215 @default.
• W2978171357 hasRelatedWork W2378044772 @default.
• W2978171357 hasRelatedWork W2387293784 @default.
• W2978171357 hasRelatedWork W3028690760 @default.
• W2978171357 hasVolume "109" @default.
• W2978171357 isParatext "false" @default.
• W2978171357 isRetracted "false" @default.
• W2978171357 magId "2978171357" @default.
• W2978171357 workType "article" @default.